Literature DB >> 28529207

Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.

Ioana D Olaru1,2, Jan Heyckendorf1,3, Sönke Andres4, Barbara Kalsdorf1,3, Christoph Lange5,3,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28529207     DOI： 10.1183/13993003.00742-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

Review 1.  In Vitro Studies of Persister Cells.

Authors:  Niilo Kaldalu; Vasili Hauryliuk; Kathryn Jane Turnbull; Agnese La Mensa; Marta Putrinš; Tanel Tenson
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-11       Impact factor: 11.056

Review 2.  Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.

Authors:  Yang Li; Feng Sun; Wenhong Zhang
Journal:  Drug Dev Res       Date:  2018-12-11       Impact factor: 4.360

3.  Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Lawrence Mbuagbaw; Lorenzo Guglielmetti; Catherine Hewison; Nyasha Bakare; Mathieu Bastard; Eric Caumes; Mathilde Fréchet-Jachym; Jérôme Robert; Nicolas Veziris; Naira Khachatryan; Tinatin Kotrikadze; Armen Hayrapetyan; Zaza Avaliani; Holger J Schünemann; Christian Lienhardt
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

Review 4.  The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review.

Authors:  Lisa Singh; Lehlohonolo J Mathibe; Varsha Bangalee
Journal:  Health SA       Date:  2021-11-29

5.  Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China.

Authors:  Xubin Zheng; Lina Davies Forsman; Ziwei Bao; Yan Xie; Zhu Ning; Thomas Schön; Judith Bruchfeld; Biao Xu; Jan-Willem Alffenaar; Yi Hu
Journal:  Eur Respir J       Date:  2022-03-24       Impact factor: 16.671

6.  Thompson loop: opportunities for antitubercular drug design by targeting the weak spot in demethylmenaquinone methyltransferase protein.

Authors:  Adeniyi T Adewumi; Opeyemi S Soremekun; Mary B Ajadi; Mahmoud E S Soliman
Journal:  RSC Adv       Date:  2020-06-19       Impact factor: 4.036

7.  A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.

Authors: 
Journal:  PLoS Biol       Date:  2022-08-09       Impact factor: 9.593

8.  Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study.

Authors:  Koné Kaniga; Akio Aono; Emanuele Borroni; Daniela Maria Cirillo; Christel Desmaretz; Rumina Hasan; Lavania Joseph; Satoshi Mitarai; Sadia Shakoor; Gabriela Torrea; Nazir Ahmed Ismail; Shaheed V Omar
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

Review 9.  Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.

Authors:  Francesco Pecora; Giulia Dal Canto; Piero Veronese; Susanna Esposito
Journal:  Microorganisms       Date:  2021-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.